KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $99.4 million.

  • Vertex Pharmaceuticals' Change in Receivables rose 24405.8% to $99.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $347.3 million, marking a year-over-year increase of 24974.82%. This contributed to the annual value of $347.3 million for FY2025, which is 24974.82% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Change in Receivables is $99.4 million, which was up 24405.8% from $59.9 million recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Change in Receivables registered a high of $251.6 million during Q1 2024, and its lowest value of -$135.1 million during Q2 2024.
  • Moreover, its 5-year median value for Change in Receivables was $55.8 million (2024), whereas its average is $58.2 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Change in Receivables soared by 153110.91% in 2021, and later tumbled by 475862.07% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Change in Receivables stood at $43.5 million in 2021, then tumbled by 123.45% to -$10.2 million in 2022, then plummeted by 50.98% to -$15.4 million in 2023, then tumbled by 348.05% to -$69.0 million in 2024, then skyrocketed by 244.06% to $99.4 million in 2025.
  • Its Change in Receivables was $99.4 million in Q4 2025, compared to $59.9 million in Q3 2025 and $18.4 million in Q2 2025.